AGP Executive Report
Last update: 14 minutes agoPBS shock for women’s health: AstraZeneca is pulling Zoladex (goserelin) from Australia from November, with limited time for existing patients, raising fears for breast cancer and endometriosis care and pointing to broader PBS listing delays. Food allergy win for parents: A new study links Australia’s earlier egg introduction guideline to a 17.7% drop in population egg allergy rates in 1-year-olds, with the biggest benefit seen in babies with early eczema. Arthritis research boost: The Albanese Government will invest $100m over a decade into arthritis and musculoskeletal conditions via a new MRFF mission, aiming to improve diagnosis and treatments for the 7+ million Australians affected. Digital health and diagnostics: Optimi Health reports its first psilocybin export to the UK for a Phase 2 trial, while Profusa pushes ahead with shareholder updates ahead of its June 23 meeting. Retail pharmacy deal watch: Sigma Healthcare confirms it’s in preliminary talks around a possible Boots sale, with no guarantee a deal will happen. Wellness culture spotlight: Australian physician Dr Anthony Chaffee, “The Carnivore Doctor,” appears at Cannes as part of a global biohacking/wellness media push. AI and nutrition tools: MyFitnessPal launches an AI Coach that turns users’ own food logs into personalised guidance.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
